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 We demonstrate a flexible, tunable scheme for synthesizing multifunctional, 
ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs) and its application to 
the area of magnetic relaxation switches. USPIO cores (10nm) were functionalized with 
a poly(propylene sulfide)-bl-poly(ethylene glycol) (PPS-PEG) copolymer, yielding ~40nm 
micelles. PPS-PEG-ssDNA conjugates and fluorophore-conjugated PPS-PEG are 
incorporated into the micelle synthesis process, yielding ssDNA-coated 
magnetofluorescent particles. To form magnetic relaxation switches, we generated 
USPIO populations that display complementary ssDNA sequences. Mixing of 
complementary USPIOs leads to clustering, resulting in a significant increase in R2 
magnetic relaxation. Treatment of the DNA-crosslinked USPIO clusters with restriction 
enzymes specific for the crosslinking sequence results in an irreversible return of R2 
relaxation to baseline levels. The constructs demonstrate their utility as nanoscale 
sensors of restriction enzyme activity. The presented functionalization scheme can be 
extended to the generation of biosensors for other sources of proteolytic activity, for 
diagnostics and imaging applications for cancer and atherosclerosis. 
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CHAPTER I 
 
INTRODUCTION 
  
The development and progression of a number of diseases, most notably cancer 
and atherosclerosis, is marked by a significant degree of proteolytic activity. These two 
conditions are the leading causes of death in the United States and in many developed 
nations worldwide. Therefore, detection of proteolytic activity using in vitro blood tests, 
or in vivo through imaging can potentially revolutionize the diagnosis and treatment of 
atherosclerosis and cancer, enabling accurate and sensitive early detection of tumors or 
vulnerable atherosclerotic plaques [1-3]. Indeed, the pathologic deregulation of 
proteases has been popularly exploited with the goals of achieving site-specific delivery 
of drugs and contrast agents to diseased tissue [4]. 
 Because of their unique properties, a wide range of nanomaterials have been 
extensively applied for biosensing. In particular, my work focuses on the application of 
ultrasmall superparamagnetic iron oxides (USPIOs) to applications involving biosensing 
of proteolytic activity. Individual USPIO cores exhibit diameters of smaller than 100nm, 
and demonstrate high R2 magnetic relaxivity, which has led to their widespread use as 
negative magnetic resonance (MR) contrast agents. A number of formulations, such as 
Feridex, have been FDA-approved for in vivo imaging applications [5]. 
 In this section, the roles of proteolysis in cancer and atherosclerosis will first be 
described. Next, this information will be used to illustrate the design of proteolytically-
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responsive biosensors, and applications of such biosensors to in vivo imaging. The novel 
“smart” contrast agents stemming from this work have the capacity to revolutionize the 
diagnosis and imaging of atherosclerosis and cancer. 
 
Roles of Proteolysis in Atherosclerosis and Cancer 
 
Proteolysis is a recurring theme in molecular biology, being important in 
processes ranging from the regulation of intracellular signaling pathways and the larger-
scale phenomena of cell-matrix interactions. Focusing on the latter, proteolysis leads to 
the release of growth factors and cellular signals entrapped within the extracellular 
matrix (ECM). These free bioactive molecules can, in turn, cause downstream 
phenotypical and behavioral changes in the local cell population. The abnormal 
upregulation of proteolytic mediators has also been signs of pathologic states, and 
proteolytic activity has been linked to cancer and atherosclerosis [6, 7]. 
Matrix metalloproteinases (MMPs) are a class of secreted or membrane-bound 
proteases that, as their name implies, recognize and degrade ECM proteins. Different 
MMPs exhibit varying levels of substrate specificity, but are generally classified based on 
their primary active substrate [8, 9]. The actions of MMPs on the cellular 
microenvironment are associated with cell proliferation and migration, angiogenesis, 
and inflammatory activity. In cancer and atherosclerosis, a collection of the listed 
biological phenomena are confirmed to be associated with various stages of disease 
progression. The pathologic deregulation of the expression of certain MMPs has been 
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correlated with abnormal manifestations of such cellular phenomena [4]. For this 
reason, MMPs have been intensely studied as a target for molecular imaging and drug 
delivery [1, 2, 10-12]. 
MMPs are overexpressed and actively involved in the progression of almost 
every human cancer, correlating with tumor invasiveness and metastasis. MMPs -2, -9, 
and -14 all promote tumor angiogenesis by degrading ECM components, releasing 
entrapped angiogenic factors (e.g. VEGF), and promoting endothelial cell invasion.  The 
same MMPs are also active in tumor cell invasion of surrounding stromal tissue and 
eventual intravasation [7]. The overexpression of MMP-7 in epithelial tumor cell lines 
results in the shedding of cell-cell adhesion molecules (e.g. E-cadherins) and other cell 
surface molecules, and is associated with the progression of colonic and breast tumors 
[9, 13]. However, not all MMPs contribute to tumor progression and invasiveness. For 
example, MMP-12 expression in lung and colon cancer models has been associated with 
host-protective anti-angiogenic effects and increased survival [7, 13, 14]. Despite this 
information, MMP inhibitors received much interest and were synthesized in the 
pharmaceuticals industry as anticancer drug candidates. However, because of these 
tumor-promoting and host-protective functions of MMPs as a family, MMP inhibitors 
have been met with very mixed results in clinical trials [1, 7, 14]. 
Atherosclerosis is an inflammatory disease where the accumulation of lipids and 
cholesterol in arterial vessel walls leads to accumulation of inflammatory cells in the 
vessel media, and formation of an atherosclerotic plaque. Plaques thicken over time and 
disrupt perfusion of downstream capillary beds, and if they occur in coronary arteries, 
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can lead to potentially fatal hypoxic conditions [15]. While the earliest stages of plaque 
formation occur in infants, pathological vascular remodeling processes destabilize the 
plaque microenvironment and increase the likelihood of plaque rupture. Ruptured 
plaques are likely to cause embolism downstream, and are associated with heart attack 
and stroke [16]. Because MMP-mediated ECM proteolysis is central to vascular 
remodeling processes, MMP activity in atherosclerotic plaques is considered to be a 
major cause of plaque rupture. The design of MMP-targeted therapeutics is expected to 
yield clinical interventions that can block the vascular remodeling that precedes plaque 
rupture [17]. Likewise, MMP-sensitive contrast agents have been designed in order to 
locate plaques that are vulnerable to rupture and identify patients that are best suited 
for more aggressive interventions [2, 18]. 
In vitro tests seeking to quantify MMP levels in serum or urine are also being 
developed for noninvasive diagnosis of diseased states [19-21]. A recent clinical study 
demonstrated that increased circulating levels of MMP-2 and MMP-9 were positively 
correlated with incidence of myocardial infarction in patients displaying atherosclerotic 
plaques [19]. Similar studies have identified MMP biomarkers for specific cancers. The 
invasiveness of colorectal cancers was positively correlated with circulating levels of 
active MMP-2 [21]. Circulating MMP-9 levels were predictive of the presence of breast 
tumors [20]. 
Therefore, MMP-responsive prodrugs, contrast agents, and biosensors have 
received much attention in the biomedical engineering community, and are 
revolutionizing modern medicine. By taking advantage of differences in MMP expression 
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and activity in pathologic versus normal states, the design of smart theranostics 
(therapeutics/diagnostics) enables more accurate detection of diseases, site-specific 
drug delivery and activity, and less invasive clinical interventions [4]. 
 
Proteolysis as a Switch for USPIO-based Biosensors in Imaging 
 
There are several design goals that must be met by proteolytically responsive 
imaging biosensors for use in vivo. Most importantly, materials that are used in this 
application must be able to specifically respond to a proteolytic environment through a 
measurable and clinically detectable change in material and/or physical properties. 
Passive and active trafficking properties to diseased areas are also very important in 
order to ensure proximity of contrast agents or drug delivery platforms to their intended 
region of activity. Finally, materials for this application (and their metabolized products) 
must be nontoxic and biocompatible. This section focuses on the first of these three 
design goals. 
For imaging, ultrasmall iron oxide nanoparticles (USPIOs) have been widely 
investigated for applications as MRI contrast agents and for probing intermolecular 
interactions due to their strong T2 magnetic relaxation properties [22-25]. As contrast 
agents, USPIOs have unique characteristics, including high detection sensitivity, 
relatively low toxicity, and long circulation half-lives [26, 27]. The ability to image deep 
tissue with good contrast makes MRI a clinically important imaging modality, compared 
to intravital fluorescence. In negative contrast mode, MRI imagers capably detect 
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changes in T2 magnetic relaxation properties within tissue volumes of interest. The 
trafficking of USPIOs to tissue results in a concentration-dependent, detectable 
decrease in local T2 relaxation [12, 28]. 
The aggregation state of USPIOs has also been previously shown to result in 
changes in material T2 relaxation properties, with clustered USPIOs exhibiting 
significantly smaller T2 relaxation times than dispersed USPIOs [12, 29, 30]. While the 
physical mechanisms behind this phenomenon remain to be explored, it is important to 
note that a number of physicochemical USPIO-based sensors have been constructed 
based on this concept. These sensors include aptamer-functionalized USPIOs for 
biochemical sensing, thermosensitive polymer-encapsulated USPIOs for combined 
imaging and drug delivery, and MMP-9-responsive sensors [12, 31, 32]. These 
nanoparticulate sensors respond to extrinsic stimuli by changing their aggregation state, 
which results in a significant change in T2 magnetic relaxation time. The resulting 
“magnetic relaxation switch” is a clinically applicable biosensor for physicochemical 
stimuli of interest. 
 
Summary 
 
In summary, the development of proteolytically-responsive biosensors has the 
potential to revolutionize the treatment, imaging, and diagnosis of cancer and 
atherosclerosis. The development of proteolytically-responsive nanoparticle 
theranostics for these diseases takes advantage of previous research demonstrating 
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nanoparticle trafficking to disease sites and site-specific drug delivery, combining these 
promising results into one injectable formulation. With this area being a relatively new 
area, there is the increasing need for nanomaterials that are suitable for this 
application. Recent work by our collaborators has yielded a poly(propylene sulfide)-bl-
poly(ethylene glycol) (PPS-PEG) block copolymer that encapsulates hydrophobic 
anticancer drugs and delivers the drugs to oxidative microenvironments that are 
characteristic of intracellular processing pathways [33, 34]. In the following chapters, we 
demonstrate the applicability of these polymers for encapsulating USPIOs, providing a 
platform onto which MRI imaging of drug delivery can be realized. 
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CHAPTER II 
 
SURFACE ENGINEERING OF IRON OXIDE NANOPARTICLES FOR IMMOBILIZATION OF 
BIOACTIVE LIGANDS 
 
Introduction 
 
 Biocompatible, bioactive USPIO-based contrast agents must be engineered to 
exhibit solubility and stability in water and, in many cases, to display ligands such as 
proteins, peptides, or nucleic acids. In order to achieve this goal, a modular approach for 
functionalizing USPIOs is generally followed. Various methods for rendering USPIOs 
water-soluble are well-documented, including covalent methods such as silanization or 
the formation of micelles with polymers or phospholipids [22, 32, 35-37]. A wide range 
of techniques in bioconjugate chemistry can then be used to immobilize bioactive 
ligands onto the USPIO surface [38]. 
 One strategy for synthesizing water-soluble USPIOs uses the coprecipitation 
method to yield dextran-coated USPIOs [22, 23]. USPIOs synthesized through the 
thermal decomposition method demonstrate superior monodispersity and can achieve 
smaller particle sizes than USPIOs synthesized by coprecipitation [22, 39-41]. Further, 
although some studies demonstrate dextran-coated USPIOs target tumors and 
cardiovascular plaques in vivo [28, 42], recent studies reveal that surface 
inhomogeneities in the dextran coating can lead to adsorption of plasma proteins onto 
the USPIO surface and consequently, rapid clearance of the USPIOs [43]. As an 
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alternative, grafting of poly(ethylene glycol) (PEG) continues to be a popular method of 
yielding “stealth” properties to nanoparticle systems because the immobilized PEG 
chains create a steric layer that discourages particle aggregation and undesirable 
particle-plasma protein interactions [44, 45]. Optimization of the pharmacokinetics and 
targeting efficiency of USPIOs for in vivo applications arguably requires the ability to 
exert fine control over the size range of the construct, but more importantly, the 
suppression of opsonization that can otherwise lead to rapid clearance of USPIOs before 
they have achieved their objectives. 
 Thermal decomposition synthesis typically yields USPIO cores coated with a layer 
of the hydrophobic surfactant oleic acid [46]. Covalent and noncovalent methods are 
available to PEGylate USPIO surfaces and render them water-soluble. In recent years, 
the encapsulation of USPIOs in micellar structures by self-assembly with amphiphilic 
PEG-containing block copolymers has received attention [32, 47, 48]. Recently, 
extensive studies by the Hubbell group have shown that amphiphilic block copolymers 
of PEG and the hydrophobic poly(propylene sulfide) (PPS) can be used to generate 
micellar and multilamellar structures for drug delivery applications [33, 49]. These 
copolymers have received interest based on their unique characteristics, including a PPS 
block capable of undergoing a hydrophobic-hydrophilic transition in oxidative 
environments, resulting in environmentally-sensitive drug release [33, 50]. Though 
previously uninvestigated as a USPIO coating, the PPS-PEG copolymers display material 
properties that can lead to the construction of novel oxidation-responsive “theranostic” 
(therapeutic-diagnostic) agents in the near future. To add to these properties, PPS-PEG 
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copolymers have been successfully tagged with bioactive ligands such as peptides [51]. 
Here, we report the broader utility of the PPS-PEG copolymer platform through the 
synthesis of PPS-PEG-ssDNA constructs and fluorophore-tagged PEG-PPS constructs, and 
the self-assembly of these constructs upon highly monodisperse USPIO cores to 
generate multifunctional magnetofluorescent nanoparticles (Scheme 1). 
 
Materials & Methods 
 
Materials 
 
 All materials and reagents were purchased from Sigma-Aldrich (St. Louis, MO) 
and used as purchased unless otherwise specified. Uranyl acetate stain was purchased 
from Electron Microscopy Sciences (Hatfield, PA). Silanes were purchased from Gelest 
(Morrisville, PA). Custom ssDNA sequences were purchased from Sigma-Genosys.  
 
Characterization of polymers by NMR and mass spectrometry 
 
 Characterization of synthesized polymers was performed using NMR, MALDI-MS, 
and electrospray-injection mass spectrometry (ESI-MS). 
 1H NMR spectra were obtained at 400 MHz using a 9.4T Oxford magnet operated 
by a Bruker AV-400 console. The main NMR probe for the instrument is a 5mm Z-
gradient broadband inverse (BBI) probe with automatic tuning and matching capability 
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(ATM). Lyophilized, pure samples were dissolved at 10mg/mL in CDCl3, then loaded into 
5mm thin-wall NMR sample tubes for measurement. 
 Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) was 
performed on a PerSeptive Biosystems Voyager System (Applied Biosystems, Foster City, 
CA). To prepare polymer samples for MALDI-MS, polymers were dissolved at a 
concentration of 2mg/mL in THF, and mixed 1:1 by volume with 40mg/mL of the matrix 
material 2-(4’-Hydroxybenzeneazo)benzoic acid (HABA). 0.5nL of the resulting polymer-
matrix mixture was then pipetted onto the sample holder and allowed to air dry for at 
least 30 min before analysis. 
 
Scheme 1 – Schematic diagram of the formation of biofunctional, water-dispersible 
magnetofluorescent particles from amphiphilic block copolymers and hydrophobic USPIO cores. 
Black fibers = PPS-PEG copolymers, Red = fluorophore (AF750; AlexaFluor-750), Yellow = ssDNA. 
 Electrospray mass spectra were recorded in positive ion mode using a Synapt 
hybrid quadrupole/oa-TOF mass spectrometer (Waters Corp., Milford, MA) equipped 
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with a dual chemical ionization/electrospray (ESCI) source. A post-acquisition gain 
correction was applied using sodium formate or sodium iodide as the lock mass. 
Polymer samples were reconstituted to a concentration of 1mg/mL in 1% acetic acid in 
THF, and then analyzed by direct injection into the mass spectrometer. 
 
Synthesis and characterization of oleic acid-coated USPIO cores 
 
 Synthesis of 10nm diameter USPIO cores was done based on the procedures 
described by Woo et al. [46]. Under argon gas flow, oleic acid (3.8mL, 12 mmol) was 
heated to 100°C in 40mL octyl ether in a three-neck flask. Fe(CO)5 (0.8mL, 6 mmol) was 
then injected into the system, and the mixture was then refluxed at 280°C for 4 h. Next, 
the mixture was cooled to 80°C and aerated overnight (>14h). The mixture was then 
refluxed for 2 h at 280°C and then cooled back to room temperature. USPIOs were 
collected following three washes in ethanol and centrifugation, and air dried overnight 
to form a dark brown-black powder. 
 Transmission electron microscopy (TEM) was conducted using a Philips CM20. 
Diluted USPIOs in toluene were dropped onto a carbon-coated copper grid (Electron 
Microscopy Sciences, Hatfield, PA) and dried naturally. This process was repeated three 
times. Images were collected using a CCD camera with AMT Image Capture Engine 
software (Advanced Microscopy Techniques, Danvers, MA), and sizing of the particles 
was automated using an ImageJ particle analyzer.  
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Synthesis of Phth-PPS-COOH 
 
 The phthalimide-protected PPS block was synthesized via anionic ring opening 
polymerization of propylene sulfide from a thioacetate-derivatized phthalimide initiator 
(Scheme 2). To form the initiator, 2.0g N-(3-acetylthiopropyl)phthalimide (7.6 mmol) 
was mixed in 40mL dry DMF in a Schlenk tube, and deprotected by addition of 1.05eq of 
0.5M sodium methoxide in methanol (9.06mL, 7.98mmol). The tube was evacuated via a 
membrane pump and equilibrated with argon 5x, and then stirred at room temperature 
for 20 min. In this step, the color of the mixture changes from bright yellow to yellow-
orange. Monomer was then added to the vessel by injection of 17eq propylene sulfide 
(10.18mL, 130 mmol) into the vial, and polymerization occurred for 90 min. In a 
separate Schlenk tube, acrylic acid (10.42mL, 152 mmol) was mixed with 13.24mL 
triethylamine (Et3N; 95 mmol), resulting in the evolution of a thick white gas. This vial 
 
Scheme 2 – Synthesis of Phth-PPS-COOH, the hydrophobic block of the PPS-PEG amphiphilic 
copolymers. 
was evacuated via a membrane pump and equilibrated with argon gas 5x, and then the 
contents were transferred under vacuum into the PPS-containing vial. Upon mixing of 
the two liquids, a color change is observed from yellow-orange to light yellow. This 
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mixture is then left to stir overnight at room temperature. Concentrated product is 
obtained by evaporation of DMF under high vacuum, and redissolved in CH2Cl2 (100mL). 
This solution was extracted 7 times in brine. The collected organic phase was then dried 
over 5g of sodium sulfate, and residual salts were removed by gravity filtration through 
a #5 Whatman filter disc. The product was concentrated by incomplete evaporation of 
the CH2Cl2 under vacuum, and then precipitated by addition to ice-cold hexanes for 30 
min. Centrifugation for 5 min at 800 x g pellets the PPS block, and the hexane extraction 
step and centrifugation is repeated a second time to yield phthalimide-protected PPS-
COOH (Phth-PPS-COOH). 
 1H NMR (400 MHz, CDCl3): δ 1.3–1.4 (d, CH3 in PPS block), 1.9–2.1 (q, N-CH2-CH2-
CH2-S between PPS and phthalimide), 2.2–2.4 (t, CH2 next to terminal carboxylic acid), 
2.5–2.8 (broad s, CH in PPS block), 2.8–3.1 (broad s, CH2 in PPS block), 3.6-3.8 (t, CH2 
adjacent to phthalimide), 7.8–8.0 (d of q, aromatic ring in phthalimide). 
 
Synthesis of PPS-PEG block copolymers 
 
 Standard carbodiimide chemistry was used to conjugate the PPS and PEG blocks. 
In a round-bottom flask, 250mg of Phth-PPS17-COOH (~1.5kDa), 100mg of 3kDa H2N-
PEG-OH (1.25:1 PPS:PEG), 5eq of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC; 
33mg), and 5.7μL of Et3N are mixed in 5mL dry DMF for 2 h at room temperature under 
argon gas. The product was concentrated by evaporation of DMF under vacuum. After 
redissolving in CH2Cl2, the product was precipitated twice in ice-cold diethyl ether 
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(Fisher Scientific, Pittsburgh, PA) and pelleted by centrifugation at 800 x g for 5 min. 
After removing the CH2Cl2 by vacuum evaporation, the product was resuspended in 
water and dialyzed overnight through 30,000 MWCO dialysis tubing (Spectrum Labs, 
Rancho Dominguez, CA). Excess water was removed by lyophilization overnight to yield 
a white powder (Phth-PPS-PEG-OH). For downstream conjugation of bioactive ligands, 
H2N-PEG-COOH was used in place of the H2N-PEG-OH described above (Scheme 1), and 
a fivefold molar excess of PPS was used in the reaction to discourage crosslinking of 
individual PEG chains, resulting in Phth-PPS-PEG-COOH. 1H NMR (400 MHz, CDCl3): δ 
1.3–1.4 (d, CH3 in PPS block), 2.1–2.3 (s, N-CH2-CH2-CH2-S between PPS and 
phthalimide), 2.4–2.7 (d, CH in PPS block), 2.8–3.0 (d, CH2 in PPS block), 3.3–3.4 (s, N-
CH2 between PPS and phthalimide), 3.4–4.0 (broad t, PEG O-CH2CH2), 6.8–6.9 (s, CONH 
bridging PPS and PEG blocks), 7.8–8.0 (t, aromatic ring in phthalimide). 
 
Synthesis of PPS-PEG-ssDNA conjugates 
 
 For ssDNA-functionalized polymers, two sequences were purchased, all with the 
5’-C6-amine modification: C1 (5’-ACG TAC GTG AT↓AT CTG CAT GCA-3’) and C2 (5’-TGC 
ATG CAG AT↓AT CAC GTA CGT-3’). The hybridization of these two sequences forms an 
EcoRV cleavage site (indicated by arrows; blunt end). These sequences (~150μg, ~20 
nmol provided) were conjugated with Phth-PPS-PEG-COOH using the same procedures 
used for the synthesis of PPS-PEG copolymers, yielding Phth-PPS-PEG-ssDNA conjugates. 
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Synthesis of fluorescently-tagged PPS-PEG.  
 
 To synthesize Alexa Fluor 750-functionalized copolymers (AF-PPS-PEG), 100mg 
Phth-PPS-PEG-OH was first deprotected by refluxing at 120ºC for 4 h in 20mL methanol 
containing roughly 3-fold molar excess of hydrazine hydrate. The product mixture was 
then concentrated under vacuum, and redispersed in 3N KOH. The polymer was 
extracted 7 times in CH2Cl2 and precipitated in ice-cold diethyl ether, yielding H2N-PPS-
PEG-OH. Confirmation of successful deprotection was done using a ninhydrin assay. The 
product was then dissolved in CH2Cl2, then reacted with Alexa Fluor 750-succinimide 
ester (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions, under an 
inert gas environment. The product was collected by ice-cold ether extraction. Free dye 
was removed through extensive dialysis of the concentrated product in water using 
10,000 MWCO dialysis tubing. Finally, lyophilization of the retentate yielded a fine, light 
blue powder. 
 
Formation and physical characterization of PEG-PPS-USPIO micelles 
 
 A co-solvent evaporation method was used to generate PEG-PPS-USPIO micelles 
[52]. Briefly, PPS-PEG copolymers (11mg) and 2mg of oleic acid-coated USPIO cores 
were dissolved in 500μL THF. This solution was sonicated briefly to break apart clumps 
of USPIOs. The solution was then added dropwise to 3mL of HPLC-grade water with 
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swirling, followed by evaporation of the organic solvent in a vacuum desiccator for 2h at 
room temperature. 
 To extract unbound polymer, the micelle mixture was then washed multiple 
times with HPLC-grade water through a 30,000 MWCO ultrafiltration centrifugal filter 
(Corning, Lowell, MA), at 1000 x g, for 1 h. The pellet was then magnetically isolated and 
washed 3 times in HPLC-grade water. The final product was resuspended in phosphate-
buffered saline for further experimentation. 
 To form magnetofluorescent micelles displaying ssDNA, PPS-PEG-ssDNA (1mg) 
and AF-PPS-PEG (<1mg) was incorporated into the initial copolymer-USPIO mixture in 
THF before dropwise addition to water. 
 Micelle sizes were characterized using TEM and dynamic light scattering (DLS). 
To prepare micelles for TEM, copper TEM grids were dipped into aqueous mixtures 
containing micelles of interest and allowed to dry in a vacuum desiccator for 2h. The 
grids were then stained with an aqueous 3% uranyl acetate solution for 30s and then 
blotted dry. Samples were dried in a vacuum desiccator for 1h before imaging on TEM as 
described above. The hydrodynamic diameters of PEG-PPS-USPIOs were measured in 
PBS using a Malvern Instruments Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK). 
 Fluorescence emission spectra of magnetofluorescent USPIO micelle 
formulations in PBS were characterized using a Jobin Yvon/Horiba Fluorolog-3 FL3-111 
spectrofluorimeter (Horiba Scientific, Edison, NJ). Because the only fluorophores used 
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for this study were Alexa Fluor 750 dyes (Invitrogen, Carlsbad, CA), samples were 
excited at 750nm, and emission spectra were collected from 770-850nm. 
 
Phenanthroline assay for iron content determination 
 
 To quantify the concentration of iron in all PEG-PPS-USPIO formulations, the 
1,10-phenanthroline assay was used [53]. USPIOs in PBS (50μL) were mineralized by 
treatment in concentrated H2SO4 for 30min at room temperature, resulting in a loss of 
the dark brownish-black color of the solution. This was followed by treatment of the 
mixture with 10μL 100mg/mL hydroxylammonium chloride in water and 50μL 1mg/mL 
1,10-phenanthroline in water. Development of an intense orange color, corresponding 
to the presence of iron, is observed upon addition of 1100μL 100mg/mL sodium acetate 
in water. Absorbance at 510nm was measured on a Varian Cary 5000 UV-Vis-NIR 
spectrophotometer (Palo Alto, CA). The concentration of free iron was calculated based 
on a standard curve constructed using serial dilutions of ferrous ammonium sulfate 
(Fisher Scientific, Pittsburgh, PA) in water. Measurements of each sample were done in 
triplicate. 
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Results 
 
Synthesis and characterization of biofunctional PPS-PEG block amphiphilic copolymers 
 
Figure 1 – ESI-MS sweeps (m/z vs. detected intensity of sample normalized as percentage of 
most abundantly detected substance) of PEG (A), Phth-PPS-COOH (B), and Phth-PPS-PEG-COOH 
(C). PEG 3000 (Sigma) spectrum is consistent with expected m/z distributions where z = +1, +2, 
+3. PPS spectrum is consistent with expected m/z distributions of z = +1, and peak spacing of 
~74 m/z is expected of the propylene sulfide monomer. Phth-PPS-PEG-COOH spectrum is 
consistent with expected m/z distributions of z = +2, +3, +4. Results are consistent with 
successful synthesis of PPS-PEG block copolymers. 
  
 The desired PPS-PEG copolymers and derivatives, and the subsequent one-step 
functionalization of USPIOs, are all illustrated in Scheme 1. Conjugation of the PPS block 
(1.2 kDa) to the PEG block (3 kDa) was characterized by ESI-MS with 0.1% acetic acid in 
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THF as the mobile phase (Figure 1). Successful conjugation is noted based on the 
disappearance of the PEG z = +1, +2, and +3 spectra and the PPS z = +1 spectra. The peak 
distributions exhibited by the PPS-PEG conjugates in the m/z ranges of interest were 
consistent with those expected of PPS-PEG at z = +2, +3, and +4. Light scattering 
measurements of the polymer mixtures were performed, and the lack of any peaks 
suggested that the polymers did not exist in micellar form in this solvent system (data 
not shown). 
Table 1. Physical Properties of Polymer-USPIO Micelle Formulations 
Sample Attached DNA Sequencea Mean Hydrodynamic Diameters ± SD (nm) 
R2 ± SD (mM-1 
s-1) 
PEG-PPS-USPIO ----- 40 ± 5 460 ± 20 
C1-USPIO C1 (5’-ACG TAC GTG AT↓AT CTG CAT GCA-3’) 85 ± 15 460 ± 90 
C2-USPIO C2 (5’-TGC ATG CAG AT↓AT CAC GTA CGT-3’) 113 ± 23 450 ± 150 
C1-USPIO + C2-
USPIO 
Hybridization of C1 & C2 to 
crosslink USPIOs 178 ± 36 690 ± 230 
a Arrows on ssDNA sequences indicate EcoRV restriction enzyme cleavage site when sequence 
has hybridized with complementary ssDNA sequence. 
 
 ssDNA sequences (22 nucleotides, 6.9 kDa each) were conjugated to Phth-PPS-
PEG-COOH using carbodiimide chemistry. The PPS-PEG-ssDNA conjugates were analyzed 
by MALDI-MS (data not shown). Successful conjugation of the sequences to the 
polymers was characterized by a disappearance of the 3.7 kDa band corresponding to 
the copolymer. 
 After synthesis and dialysis, AF-PPS-PEG was dissolved in water and analyzed by 
spectrofluorimetry. Successful synthesis of the polymer was characterized by the 
appearance of a fluorescence emission peak at ~810nm, with respect to the starting 
material (Figure 3). 
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PPS-PEG functionalized iron oxide-containing micelles and their physical properties 
 
Figure 2 – High resolution TEM images of (A) 10nm USPIO cores, and the ssDNA-functionalized 
PPS-PEG block copolymer-encapsulated USPIO micelles designated (B) C1-USPIOs and (C) C2-
USPIOs. The micelles contain aggregates of multiple USPIO cores. Scale bars = 20nm, 500nm, & 
500nm, respectively. 
 Gram quantities of 10 ± 1nm oleic acid-coated USPIO cores were synthesized 
using a thermal decomposition method [46]. The cores were then deposited on a carbon 
grid and imaged by TEM (Figure 2a), and demonstrated regular inter-particle spacing 
characteristic of highly monodisperse nanoparticles. Following the functionalization with 
PPS-PEG copolymers, the USPIOs displayed average hydrodynamic diameters of 40 ± 
5nm (Table 1). This large increase in diameter is partly due to the encapsulation of 
multiple USPIO cores within each micelle (Figure 2). Nevertheless, the functionalization 
process yields water-dispersible USPIOs that remain stable in suspension for months. 
 Apparently successful functionalization of OA-capped USPIOs with the block 
copolymer alone was extended to provide a single step synthesis of USPIOs with 
bioactive functionalities of interest. In this case, PPS-PEG-ssDNA constructs were 
incorporated into the USPIO micelles, resulting in two complementary populations of 
ssDNA-USPIOs referred to as C1-USPIO and C2-USPIO. The incorporation of PPS-PEG-
ssDNA conjugates into micelle formation generally led to larger hydrodynamic 
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diameters as determined by light scattering measurements (Table 1). This is evidenced 
by the increased average hydrodynamic diameter to approximately 100nm across all 
ssDNA-functionalized USPIO samples. This large increase in hydrodynamic diameter may 
suggest some extent of particle aggregation in situ, and this is confirmed by TEM images 
of the USPIO-containing micellar structures (Figure 2b-2c).  
 
Figure 3 – Emission spectra of free AlexaFluor-tagged PPS-PEG copolymer (AF-PPS-PEG; solid) 
and AF-PPS-PEG incorporated into USPIO micelles (AF-PPS-PEG-USPIOs; dotted) obtained by 
excitation of samples at 750nm. Emission intensity is reported in arbitrary units (cps; counts per 
second). Spectral differences stem from the microenvironment where the AF dye is located. As a 
negative control, the emission spectrum of PEG-PPS-USPIO without the fluorescent tag (PEG-
PPS-USPIO; dashed) is shown.  
 
 Finally, fluorescently tagged copolymer was also incorporated into the micelle 
formation process, resulting in magnetofluorescent USPIO micelles (Figure 3). Compared 
to free AF-PPS-PEG, the complexed AF-PPS-PEG exhibited a blue shift in the fluorescence 
emission peak from ~810nm to ~785nm. 
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Discussion 
 
 In this section, the flexible one-step functionalization of USPIOs with bioactive 
ligands and PEG was demonstrated. Highly monodisperse 10nm USPIO cores were 
encapsulated into >40nm micelles containing multiple cores each (Figure 2). While the 
micelles are less monodisperse than the original cores, this result appears to be a 
product of the micelle formation process. Other groups have used alternative 
amphiphilic block copolymers to encapsulate USPIOs and experienced similar results 
[32, 48]. In the cited work, the amphiphlic copolymers exhibited molecular weights 
above 5kDa, compared to the 1.5kDa used in the studies here. While the polymers are 
very different, it may be possible to exert control over micelle size and the number of 
USPIO cores per micelle by varying the length and molecular weight of the hydrophobic 
block in the amphiphilic copolymers. By significantly decreasing the length of the 
hydrophobic block, it may be possible to produce micelles containing single USPIO cores 
each, for similar reasons as self-assembled monolayer formation on gold surfaces. In 
this way, product micelle monodispersity is dictated solely by the monodispersity of the 
USPIO cores and the polydispersity index of the amphiphilic copolymers used. 
 Upon incorporation of AF-PPS-PEG to the USPIO micelles, a blue shift in the 
fluorescence emission peak was observed. This blue shift phenomenon has been 
previously reported for magnetofluorescent nanobeads using USPIO-quantum dot core-
shell structures [54-56]. Known as the dynamic Stokes shift in solution, the phenomenon 
is observed when changing the microenvironment wherein fluorophores are adsorbed 
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or dissolved [57]. Because the AF dye used in our studies was coupled to the 
hydrophobic block of the polymers, its physical position in the micelle is expected to be 
within the hydrophobic layer between the USPIO surface and the PEG corona. This 
microenvironment is very different from the aqueous medium used to analyze the 
polymers without the USPIOs present. 
 Given the extensive use of carbodiimide chemistry to couple bioactive ligands 
through a relatively stable amide linkage to the polymer backbone, the presented 
reaction schemes are expected to be very applicable for coupling peptides, proteins and 
other moieties to the polymer. From there, the micelle formation process enables the 
stable display of such moieties on the USPIO surface. 
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CHAPTER III 
 
THE MAGNETIC RESONANCE SWITCH: ENZYMATICALLY-CLEAVABLE IRON OXIDE 
NANOPARTICLE CLUSTERS AS BIOSENSORS OF PROTEOLYTIC ACTIVITY 
 
Introduction 
 
 To demonstrate the applicability of the USPIO functionalization approach 
described in the previous section, ssDNA-tagged USPIOs will be used as magnetic 
relaxation switches (MRS) [29, 30, 58]. The MRS concept indicates that clustering of 
USPIOs leads to a significant increase in R2 relaxivity of the USPIOs, while declustering 
returns relaxivity to baseline levels. The MRS label originated from the behavior of the 
system as a nanosensor capable of being turned on or off in the presence of a specific 
environmental stimulus, which, for our demonstration purposes, is restriction enzyme 
activity. Though the ultimate goal is to produce MMP-responsive biosensors, the USPIO 
functionalization scheme is flexible enough to accommodate alternative biomolecules 
other than ssDNA, and the presented work provides a proof of concept of the utility of 
our fabrication scheme for future work. 
 Complementary populations of ssDNA-USPIOs were mixed to form clusters. 
These clusters were subjected to restriction enzyme treatment or thermocycling to 
decluster the USPIO cores irreversibly or reversibly. Light scattering and relaxation 
measurements were carried out on clustered and declustered MRS in aqueous solution. 
Altogether, the work presented here offers a flexible platform for generating highly 
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monodisperse, multifunctional magnetofluorescent nanoparticles that are dispersible in 
water and enable biosensing by modulation of image contrast.  
 
Materials & Methods 
 
R2 relaxation measurements 
 
 A 0.5T Maran tabletop NMR scanner with DRX-II console (Oxford Instruments, 
Oxfordshire, UK) was used for transverse (T2) relaxation time measurements. 200μL of 
PEG-PPS-USPIOs in PBS were loaded into 5-mm thin-walled NMR tubes and introduced 
into the scanner. Measurements were made using a Carr-Purcell-Meiboom-Gill (CPMG) 
sequence at room temperature, 32 echoes with 12ms time between echoes, and an 
average of 9 acquisitions. R2 relaxation coefficients were calculated based on the 
following formula [59], where [Fe] is the iron content of the sample as determined 
through the phenanthroline assay (described earlier): 
𝑅𝑅2 =  1𝑇𝑇2  ×  [𝐹𝐹𝐹𝐹] (1)  
 For clustering/declustering experiments, 100μL of complementary ssDNA-USPIO 
populations were mixed in the NMR tubes and allowed 10min to cluster before T2 was 
remeasured as described above. To study the effects of restriction enzyme treatment, 
500U of EcoRI or EcoRV were added to the tubes according to the manufacturer’s 
instructions and the system was incubated at 37°C for 4 h before relaxation time was 
remeasured. To study the effects of thermocycling, samples in NMR tubes were heated 
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to 85°C in a water bath for 15 min, then measured in the relaxometer. The 
temperatures in heated ssDNA-USPIO samples did not drop below 70°C during the 
measurement process. Unless otherwise noted, all presented data is the average of 
three independent experiments. 
 
Results 
 
Clustering of complementary USPIOs leads to increase in R2 relaxivity coefficients  
 
Figure 4 - Self-assembly of EcoRV-sensitive ssDNA-USPIO clusters, and subsequent enzymatic 
treatment results in measurable changes in R2 relaxation coefficient normalized to initial values.  
Following EcoRV treatment, R2 values return to baseline, a phenomenon that is in significant 
contrast to the effects of EcoRI treatment of the same clusters (n = 6). * p < 0.05 
 
 R2 coefficients were calculated based on measurements of USPIO iron content 
through the phenanthroline assay [53] and relaxation time measurements. For all 
polymer-USPIO micelle samples, R2 values ranged between 400-500 mM-1 s-1 (Table 1). 
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When C1-USPIOs and C2-USPIOs were mixed, the hybridization of the surface-
immobilized ssDNA sequences results in crosslinking of the USPIOs into larger clusters. 
This response is observed via an increase in hydrodynamic diameters to 178 ± 36nm, 
and an increase in R2 coefficient to 690 ± 230 mM-1 s-1 (Table 1). 
 
Enzymatic treatment and thermocycling of USPIO clusters and effects on R2  
 
Figure 5 – Thermocycling of DNA-crosslinked USPIO clusters results in measurable changes in R2 
relaxation coefficient. Heating of the clusters melts the DNA and results in declustering of the 
particles, corresponding to an approximately 50% decrease in R2 coefficient. After allowing the 
system to cool, the R2 coefficient increases to original levels, suggesting the reclustering of the 
ssDNA-USPIOs (n = 3). 
 
 Since clustering of the complementary C1-USPIOs and C2-USPIOs resulted in 
expected changes in R2, the next goal was to determine whether reversal of the 
clustering process would likewise correspondingly reverse the observed increase in R2. 
Irreversible and reversible ‘declustering’ of the USPIO complexes was achieved through 
enzymatic treatment and through thermocycling experiments, respectively. 
 By design, the hybridization of USPIO-immobilized C1- and C2- sequences reveals 
an EcoRV blunt end cleavage site. Treatment of the clusters with EcoRV is thus expected 
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to redisperse the individual micelles, resulting in irreversible return of the R2 values to 
the baseline levels prior to the formation of the clusters. This expectation is confirmed 
by relaxometry data (Figure 4), where a significant difference in R2 (p < 0.05) is 
measured following treatment with EcoRV. In contrast, clusters were alternatively 
treated with EcoRI as a negative control, and the lack of a declustering response is 
reflected in an insignificant change in the R2 coefficient of the system. 
 Next, reversible declustering of the USPIOs was achieved through thermocycling, 
where R2 measurements were made while the USPIO clusters were being subjected to 
heating and cooling. In this process, heating and cooling of the clusters melts and 
reanneals the crosslinking DNA sequences, respectively. The resulting changes in the 
clustering of USPIOs leads to expected fluctuations in R2 (Figure 5). The heated clusters 
are expected to decluster, resulting in the return of R2 values to baseline levels prior to 
mixing C1-USPIOs and C2-USPIOs. Allowing the system to cool is expected to reanneal 
the DNA sequences and reform clusters, returning R2 levels to the ranges expected for 
clusters. Heating of the clusters resulted in approximately 50% decrease in R2, while 
return of the system to room temperature resulted in recovery of the original R2. 
 
Discussion 
 
 The magnetic relaxivities of the ssDNA-functionalized particles were investigated 
and compared to other polymer-encapsulated USPIO formulations. The measured R2 
values were well within expected ranges, and are similar in order of magnitude to those 
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recently measured by LaConte et al and Lee et al [59, 60]. Differences in the absolute R2 
values reported are easily accounted for, since LaConte et al used USPIO cores of 
smaller diameters (~6nm), while Lee et al used USPIO cores that had been doped with 
other metals such as manganese. Upon clustering complementary ssDNA-USPIOs, a 
significant increase in R2 was observed (Table 1). This phenomenon is consistent with 
previously published results [48][29, 48, 58, 61]. The mechanisms behind this “MRS” 
effect remains largely unstudied and is the subject of an ongoing study in our group. 
 The goal of treating USPIO clusters with restriction enzymes is to induce 
irreversible redispersion of the USPIO clusters. EcoRV treatment resulted in redispersed 
USPIOs that did not reform the original DNA-crosslinked clusters, while EcoRI treatment 
did not result in any significant changes in the R2 values of the samples. In the 
thermocycling experiments, the data suggests that the USPIO clusters are indeed 
crosslinked by DNA, as the PCR-inspired thermal fluctuations subjected the clusters to 
reversible declustering. Our data matched the expected behavior of such a system 
under the subjected conditions, and the trends are within agreement with previously 
published results by Weissleder’s group using USPIOs functionalized through an 
alternative route [29, 58]. 
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CHAPTER IV 
 
CONCLUSIONS 
 
Novel PPS-PEG based polymers were synthesized and characterized, then 
applied as a USPIO coating in a one-step co-solvent evaporation method to yield USPIO 
micelles. The synthesis of fluorescently tagged polymers and ssDNA-tagged polymers 
and the incorporation of these species into the micelle formation process leads to the 
relatively simple formation of multifunctional USPIO micelles. The generation of 
complementary populations of ssDNA-USPIOs results in a system that is capable of 
detecting proteolytic events through significant changes in R2 relaxation coefficient of 
the system. Therefore, the presented USPIO functionalization scheme results in 
bioactive nanoparticulate agents that can be extended to in vitro and in vivo biosensing 
applications in the future. 
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CHAPTER V 
 
ONGOING AND FUTURE WORK 
 
The presented work serves as preliminary data to my ongoing work where the 
USPIO crosslinkers (DNA in this work) are now MMP-degradable peptides. When 
complete, the peptide-crosslinked USPIO micelle clusters will serve as a candidate for in 
vivo molecular imaging of MMP activity. Ongoing experiments examine the behavior of 
the USPIO nanoclusters in vitro in cultures of immune cells such as macrophages, which 
are among the important MMP-releasing cell types in vulnerable atherosclerotic 
plaques. In vivo experiments in murine models of atherosclerosis have been proposed 
for this project. These smart contrast agents will hone in on cancer tumors and 
atherosclerotic plaque sites, only becoming activated in the presence of proteolytic 
microenvironments that signify specific stages of disease. This technology will enable 
better diagnosis of a patient’s condition and more accurate assignment of treatment 
options. 
Further, the materials used in this study have been previously used for 
intracellular drug delivery, enabling the realization of a “theranostic” platform for 
imaging drug localization and delivery to sites of interest in the body.  
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